Peringatan Keamanan

Oral LD50 in rats is 7400 mg/kg. Symptoms which may occur in case of overdose include, but are not limited to, muscular weakness and alterations in the state of consciousness (e.g., lethargy, coma), vomiting, diarrhea, and crystalluria.

Dantrolene

DB01219

small molecule approved investigational

Deskripsi

Chemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin.

Struktur Molekul 2D

Berat 314.257
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The mean biologic half-life after intravenous administration is variable, between 4 to 8 hours under most experimental conditions, while oral is 8.7 hours for a 100mg dose.
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Bioavailability is 70%.

Metabolisme

Hepatic, most likely by hepatic microsomal enzymes. Its major metabolites in body fluids are 5-hydroxydantrolene and an acetylamino metabolite of dantrolene. Another metabolite with an unknown structure appears related to the latter. Dantrium may also undergo hydrolysis and subsequent oxidation forming nitrophenylfuroic acid.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Take with or without food. The absorption is unaffected by food.

Interaksi Obat

1077 Data
Buprenorphine Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
Hydrocodone Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
Methotrimeprazine Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Dantrolene may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
Mirtazapine Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
Orphenadrine Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
Pramipexole Dantrolene may increase the sedative activities of Pramipexole.
Ropinirole Dantrolene may increase the sedative activities of Ropinirole.
Rotigotine Dantrolene may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Dantrolene.
Sodium oxybate Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
Thalidomide Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Vecuronium The therapeutic efficacy of Vecuronium can be increased when used in combination with Dantrolene.
Succinylcholine The therapeutic efficacy of Succinylcholine can be increased when used in combination with Dantrolene.
Metocurine iodide The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Dantrolene.
Gallamine triethiodide The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Dantrolene.
Cisatracurium The therapeutic efficacy of Cisatracurium can be increased when used in combination with Dantrolene.
Rocuronium The therapeutic efficacy of Rocuronium can be increased when used in combination with Dantrolene.
Atracurium besylate The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Dantrolene.
Doxacurium The therapeutic efficacy of Doxacurium can be increased when used in combination with Dantrolene.
Mivacurium The therapeutic efficacy of Mivacurium can be increased when used in combination with Dantrolene.
Decamethonium The therapeutic efficacy of Decamethonium can be increased when used in combination with Dantrolene.
Metocurine The therapeutic efficacy of Metocurine can be increased when used in combination with Dantrolene.
Pancuronium The therapeutic efficacy of Pancuronium can be increased when used in combination with Dantrolene.
Pipecuronium The therapeutic efficacy of Pipecuronium can be increased when used in combination with Dantrolene.
Rapacuronium The therapeutic efficacy of Rapacuronium can be increased when used in combination with Dantrolene.
Pyrantel The therapeutic efficacy of Pyrantel can be increased when used in combination with Dantrolene.
Neosaxitoxin The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Dantrolene.
Atracurium The therapeutic efficacy of Atracurium can be increased when used in combination with Dantrolene.
Gallamine The therapeutic efficacy of Gallamine can be increased when used in combination with Dantrolene.
Alcuronium The therapeutic efficacy of Alcuronium can be increased when used in combination with Dantrolene.
Tubocurarine The therapeutic efficacy of Tubocurarine can be increased when used in combination with Dantrolene.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Dantrolene.
Magnesium sulfate The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Magnesium sulfate.
Isradipine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Isradipine.
Diltiazem The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Diltiazem.
Trimethadione The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Trimethadione.
Amlodipine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Amlodipine.
Nimodipine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Nimodipine.
Nisoldipine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Nisoldipine.
Lercanidipine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Lercanidipine.
Cinnarizine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Cinnarizine.
Ethosuximide The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Ethosuximide.
Nicardipine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Nicardipine.
Verapamil The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Verapamil.
Loperamide The risk or severity of hyperkalemia can be increased when Loperamide is combined with Dantrolene.
Zonisamide The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Zonisamide.
Felodipine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Felodipine.
Nitrendipine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Nitrendipine.
Perhexiline The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Perhexiline.
Nifedipine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Nifedipine.
Amiodarone The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Amiodarone.
Carvedilol The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Carvedilol.
Bepridil The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Bepridil.
Mibefradil The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Mibefradil.
Nimesulide The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Nimesulide.
Prenylamine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Prenylamine.
Cyclandelate The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Cyclandelate.
Flunarizine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Flunarizine.
Fluspirilene The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Fluspirilene.
Clevidipine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Clevidipine.
Methsuximide The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Methsuximide.
Seletracetam The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Seletracetam.
Nylidrin The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Nylidrin.
Ziconotide The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Ziconotide.
Dotarizine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Dotarizine.
Nilvadipine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Nilvadipine.
Tranilast The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Tranilast.
Fasudil The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Fasudil.
Agmatine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Agmatine.
Fendiline The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Fendiline.
Eperisone The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Eperisone.
Trimebutine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Trimebutine.
Pinaverium The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Pinaverium.
Barnidipine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Barnidipine.
Aranidipine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Aranidipine.
Azelnidipine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Azelnidipine.
Benidipine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Benidipine.
Cilnidipine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Cilnidipine.
Darodipine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Darodipine.
Efonidipine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Efonidipine.
Lacidipine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Lacidipine.
Manidipine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Manidipine.
Niguldipine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Niguldipine.
Niludipine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Niludipine.
Carboxyamidotriazole The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Carboxyamidotriazole.
Naftopidil The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Naftopidil.
Tetrahydropalmatine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Tetrahydropalmatine.
Vinpocetine The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Vinpocetine.

Target Protein

Ryanodine receptor 1 RYR1

Referensi & Sumber

Synthesis reference: Davis, C.S. and Snyder, H.R. Jr.; US. Patent 3,415,821; December 10, 1968; assigned to The Norwich Pharmacal Company.
Artikel (PubMed)
  • PMID: 15023108
    Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F: Dantrolene--a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004 Apr;59(4):364-73.

Contoh Produk & Brand

Produk: 50 • International brands: 1
Produk
  • Agilus
    Injection, powder, for solution • 5.3 mg/ml • Intravenous • EU • Approved
  • Agilus
    Injection, powder, for solution • 5.3 mg/ml • Intravenous • EU • Approved
  • Dantrium
    Capsule • 25 mg/1 • Oral • US • Approved
  • Dantrium
    Capsule • 50 mg/1 • Oral • US • Approved
  • Dantrium
    Capsule • 100 mg/1 • Oral • US • Approved
  • Dantrium
    Injection • 20 mg/60mL • Intravenous • US • Approved
  • Dantrium
    Injection • 20 mg/60mL • Intravenous • US • Approved
  • Dantrium
    Capsule • 25 mg/1 • Oral • US • Approved
Menampilkan 8 dari 50 produk.
International Brands
  • Dantamacrin — Spepharm

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul